Alaunos Therapeutics Inc Total Assets
Alaunos Therapeutics Inc total assets. Based on the latest financial reports, Alaunos Therapeutics Inc (TCRT) holds total assets worth $1.52 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see TCRT stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Alaunos Therapeutics Inc (2001–2025)
Total assets of Alaunos Therapeutics Inc from 2001 to 2025. This chart illustrates how Alaunos Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See current stock price of Alaunos Therapeutics Inc for real-time trading data and today's change.
Alaunos Therapeutics Inc - Asset Composition Analysis
Alaunos Therapeutics Inc Total Assets Breakdown (December 2025)
Alaunos Therapeutics Inc total assets breakdown as of December 2025. Alaunos Therapeutics Inc's total assets of $1.52 Million consist of 67.0% current assets and 33.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 46.7% |
| Accounts Receivable | $3.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2025)
This chart illustrates how Alaunos Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore TCRT net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Alaunos Therapeutics Inc's current assets represent 67.0% of total assets in 2025, an increase from 31.8% in 2001.
- Cash Position: Cash and equivalents constituted 46.7% of total assets in 2025, up from 15.6% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 33.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Alaunos Therapeutics Inc Competitors by Total Assets
Key competitors of Alaunos Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Genmab A/S
CO:GMAB
|
Denmark | Dkr7.02 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Xizang Haisco Pharmaceutical Group Co Ltd
SHE:002653
|
China | CN¥7.88 Billion |
|
Abivax SA American Depositary Shares
NASDAQ:ABVX
|
USA | $462.21 Million |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Viking Therapeutics Inc
NASDAQ:VKTX
|
USA | $521.90 Million |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
Alaunos Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.77 | 3.48 | 3.43 |
| Quick Ratio | 0.77 | 3.48 | 3.43 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-198.00K | $2.66 Million | $68.38 Million |
Alaunos Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Alaunos Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.60 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | 7.7% |
| Total Assets | $2.97 Million |
| Market Capitalization | $2.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Alaunos Therapeutics Inc's assets below their book value (0.77x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Alaunos Therapeutics Inc's assets grew by 7.7% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Alaunos Therapeutics Inc (2001–2025)
The table below shows the annual total assets of Alaunos Therapeutics Inc from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $2.97 Million | +7.66% |
| 2024-12-31 | $2.75 Million | -66.66% |
| 2023-12-31 | $8.26 Million | -87.28% |
| 2022-12-31 | $64.94 Million | -31.55% |
| 2021-12-31 | $94.86 Million | -35.18% |
| 2020-12-31 | $146.34 Million | +34.12% |
| 2019-12-31 | $109.11 Million | +14.80% |
| 2018-12-31 | $95.05 Million | -9.99% |
| 2017-12-31 | $105.61 Million | -0.70% |
| 2016-12-31 | $106.35 Million | -30.82% |
| 2015-12-31 | $153.72 Million | +239.82% |
| 2014-12-31 | $45.24 Million | -36.96% |
| 2013-12-31 | $71.75 Million | -13.97% |
| 2012-12-31 | $83.40 Million | -22.85% |
| 2011-12-31 | $108.11 Million | +75.73% |
| 2010-12-31 | $61.52 Million | +23.69% |
| 2009-12-31 | $49.74 Million | +295.58% |
| 2008-12-31 | $12.57 Million | -65.77% |
| 2007-12-31 | $36.73 Million | +24.45% |
| 2006-12-31 | $29.51 Million | +210.91% |
| 2005-12-31 | $9.49 Million | +45201323.81% |
| 2004-12-31 | $21.00 | -36.36% |
| 2003-12-31 | $33.00 | -93.41% |
| 2002-12-31 | $501.00 | -82.63% |
| 2001-12-31 | $2.88K | -- |
About Alaunos Therapeutics Inc
Alaunos Therapeutics, Inc., a pre-clinical stage biopharmaceutical company that develops orally administered small-molecule therapeutics for the treatment of obesity and related metabolic disorders. It develops non-hormonal, non-incretin approach, and unlike hormone-based treatments, such as GLP-1 drugs. The company also develops hunTR TCR discovery platform to target driver mutations. Alaunos Th… Read more